In PrEP: Long-acting antivirals for HIV prevention
- PMID: 35143766
- DOI: 10.1016/j.chom.2022.01.012
In PrEP: Long-acting antivirals for HIV prevention
Abstract
Two recent publications (Vidal et al., 2021; Xue et al., 2022) report highly potent inhibitors as candidates for HIV pre-exposure prophylaxis (PrEP). They provide strong evidence that administration of long-acting capsid or fusion inhibitors as PrEP offers robust protection against simian-human immunodeficiency virus in the rhesus macaque model of HIV infection.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The author declares no competing interests.
Comment on
-
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges.Nature. 2022 Jan;601(7894):612-616. doi: 10.1038/s41586-021-04279-4. Epub 2021 Dec 7. Nature. 2022. PMID: 34875675 Free PMC article.
-
Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide.Cell. 2022 Jan 6;185(1):131-144.e18. doi: 10.1016/j.cell.2021.11.032. Epub 2021 Dec 16. Cell. 2022. PMID: 34919814
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
